While I agree they're diversified, and the upcoming presentations at AACR has some products that previously have not been discussed, most of the products they've developed or are working with partners are in early stage clinical or preclinical development. IMGN853 is the only product that in the immediate future can provide routine earnings.
All this could change with one or more new partnership, or perhaps a current partner taking a big step into a pivotal trial, but barring that IMGN853 is the product that should bring in earnings that could eventually reach billions a year. It will probably be the middle of the next decade before other products reach approval consideration.
Gary
News 
Market Data 
Discover 
